title: Treatment of patients with transformed lymphoma.
abstract: Histologic transformation (HT) is a frequent event in the clinical course of patients with indolent lymphoma. Most of the available data in the literature comes from studies on transformation of follicular lymphoma (FL), as this is the most common indolent lymphoma; however, HT is also well documented following small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL), lymphoplasmacytic lymphoma (LPL), or marginal zone lymphoma (MZL), amongst other types of lymphoma, albeit most of the studies on transformation in these subtypes are case reports or short series. The outcome of patients with HT has traditionally been considered dismal with a median overall survival (OS) of around 1 year in most of the published studies. This prompted many authors to include stem cell transplant (SCT) as part of the treatment strategy for young and fit patients with HT. However, recent articles suggest that the outcome of patients with transformed lymphoma might be improving, questioning the need for such intensive therapies. The management of patients with HT is challenged by the heterogeneity of the population in terms of previous number and type of therapy lines and from their exclusion from prospective clinical trials. This review will examine whether the advent of new therapies has impacted on the prognosis of HT and on current treatment strategies.
authors.affiliation: Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
mesh_terms: D002471:Cell Transformation, Neoplastic; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D008224:Lymphoma, Follicular / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods; D012306:Risk; D000069283:Rituximab / Q000627:therapeutic use; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
chemical_list: D000069283:Rituximab